FY2026 EPS Estimates for Scholar Rock Lifted by Analyst

Scholar Rock Holding Co. (NASDAQ:SRRK) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Scholar Rock in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($1.57) per share for the year, up from their prior forecast of ($1.68). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.40) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

A number of other equities analysts have also issued reports on the company. Wedbush increased their price target on Scholar Rock from $40.00 to $47.00 and gave the company an “outperform” rating in a research note on Monday. Piper Sandler increased their price target on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Truist Financial increased their price target on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. increased their price target on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, October 14th. Finally, BMO Capital Markets increased their price target on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, October 11th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Scholar Rock has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $38.15 on Thursday. The stock has a fifty day moving average price of $23.69 and a two-hundred day moving average price of $14.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The firm has a market cap of $3.57 billion, a P/E ratio of -16.23 and a beta of 0.47. Scholar Rock has a 1 year low of $6.76 and a 1 year high of $43.38.

Insider Activity

In other news, insider Tracey Sacco sold 30,000 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the sale, the insider now owns 49,285 shares in the company, valued at approximately $1,262,681.70. This represents a 37.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $38.49, for a total value of $15,759,076.17. Following the completion of the sale, the insider now owns 10,850,005 shares of the company’s stock, valued at $417,616,692.45. The trade was a 3.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,823,322 shares of company stock worth $56,411,627. Insiders own 19.20% of the company’s stock.

Institutional Trading of Scholar Rock

A number of hedge funds have recently modified their holdings of SRRK. Vanguard Group Inc. lifted its holdings in shares of Scholar Rock by 4.0% in the first quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after purchasing an additional 114,550 shares in the last quarter. American International Group Inc. lifted its holdings in shares of Scholar Rock by 3.0% in the first quarter. American International Group Inc. now owns 28,407 shares of the company’s stock valued at $505,000 after purchasing an additional 834 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Scholar Rock in the first quarter valued at $258,000. Jane Street Group LLC lifted its holdings in shares of Scholar Rock by 95.5% in the first quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock valued at $4,339,000 after purchasing an additional 119,363 shares in the last quarter. Finally, Walleye Trading LLC purchased a new stake in shares of Scholar Rock in the first quarter valued at $178,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.